| Q39456029 | A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. |
| Q41000388 | A SWOT Analysis of the Updated National HIV/AIDS Strategy for the U.S., 2015-2020. |
| Q37034865 | A practical online tool to estimate antiretroviral coverage for HIV infected and susceptible populations needed to reduce local HIV epidemics. |
| Q37418168 | A surveillance system to assess the need for updating systematic reviews |
| Q39039319 | A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models |
| Q41512233 | A zebrafish model of conditional targeted podocyte ablation and regeneration |
| Q34697242 | Acceptability and willingness among men who have sex with men (MSM) to use a tablet-based HIV risk assessment in a clinical setting. |
| Q90461852 | An International Analysis of Dialysis Services Reimbursement |
| Q31063168 | An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis |
| Q35816145 | Angiotensin Receptor Blockers Decrease the Risk of Major Adverse Cardiovascular Events in Patients with End-Stage Renal Disease on Maintenance Dialysis: A Nationwide Matched-Cohort Study |
| Q47257220 | Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade. |
| Q34077715 | Antiretroviral chemoprophylaxis: state of evidence and the research agenda |
| Q28085433 | Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis |
| Q38165803 | Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US. |
| Q93029465 | Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury |
| Q30391917 | Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings |
| Q36603768 | Caring for patients with kidney disease: shifting the paradigm from evidence-based medicine to patient-centered care |
| Q34968312 | Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe? |
| Q36751005 | Chronic Kidney Disease Guideline Implementation in Primary Care: A Qualitative Report from the TRANSLATE CKD Study. |
| Q34294277 | Clinical effectiveness and cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men: risk calculators for real-world decision-making |
| Q34736194 | Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America |
| Q36480354 | Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation |
| Q55498884 | Concurrent renal dysfunction with ischemic heart disease is an important determinant for cardiac and cerebrovascular mortality in patients on chronic digoxin therapy for atrial fibrillation. |
| Q34621612 | Creatinine-or cystatin C-based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease |
| Q38283016 | Curcumin and chronic kidney disease (CKD): major mode of action through stimulating endogenous intestinal alkaline phosphatase |
| Q42694761 | Diastolic dysfunction and chronic kidney disease |
| Q35938045 | Early chronic kidney disease: diagnosis, management and models of care |
| Q28658226 | Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco |
| Q51103535 | Effect of estrogen deficiency on the fixation of titanium implants in chronic kidney disease mice. |
| Q37060053 | Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study). |
| Q28539234 | Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics |
| Q52315019 | Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study. |
| Q38084940 | Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis |
| Q37616702 | End-Stage Renal Disease Outcomes among the Kaiser Permanente Southern California Creatinine Safety Program (Creatinine SureNet): Opportunities to Reflect and Improve |
| Q36624166 | Estimating the long term impact of kidney donation on life expectancy and end stage renal disease |
| Q33724701 | Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis |
| Q36276035 | Explaining the Efficacy of Pre-exposure Prophylaxis (PrEP) for HIV Prevention: A Qualitative Study of Message Framing and Messaging Preferences Among US Men Who have Sex with Men. |
| Q28552357 | HIV Incidence and Predictors of Incident HIV among Men Who Have Sex with Men Attending a Sexual Health Clinic in Melbourne, Australia |
| Q37846333 | HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry |
| Q34046430 | HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial |
| Q37525283 | High risk for HIV following syphilis diagnosis among men in Florida, 2000-2011. |
| Q28552455 | How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact |
| Q35496622 | How do systematic reviews incorporate risk of bias assessments into the synthesis of evidence? A methodological study. |
| Q39321915 | Impact of Population Recruitment on the HIV Epidemics and the Effectiveness of HIV Prevention Interventions |
| Q59793415 | Impaired glomerular filtration rate, high grade albuminuria and associated factors among adult patients admitted to tertiary Hospital in Ethiopia |
| Q33556410 | Implementation of a pragmatic randomized trial of screening for chronic kidney disease to improve care among non-diabetic hypertensive veterans |
| Q40603013 | Incidence and Predictors of HIV Infection Among Men Who Have Sex with Men Attending Public Sexually Transmitted Disease Clinics, New York City, 2007-2012. |
| Q35139980 | Indices to measure risk of HIV acquisition in Rakai, Uganda |
| Q57765224 | Influencing Condom Use by Gay and Bisexual Men for Anal Sex Through Social Marketing |
| Q40482985 | Interlaboratory Variability in Plasma Creatinine Measurement and the Relation with Estimated Glomerular Filtration Rate and Chronic Kidney Disease Diagnosis. |
| Q30585651 | Interpreting treatment effects from clinical trials in the context of real-world risk information: end-stage renal disease prevention in older adults |
| Q36980140 | Joint Effect of Early Microvascular Damage in the Eye &Kidney on Risk of Cardiovascular Events |
| Q92578316 | KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline |
| Q91740512 | Kidney Health for Everyone Everywhere - From Prevention to Detection and Equitable Access to Care |
| Q90182797 | Kidney Health for Everyone Everywhere-From Prevention to Detection and Equitable Access to Care |
| Q98178877 | Kidney Health for Everyone Everywhere-From Prevention to Detection and Equitable Access to Care |
| Q90672119 | Kidney Health for Everyone Everywhere: From Prevention to Detection and Equitable Access to Care |
| Q57099518 | Kidney care in Haiti--the role of partnerships |
| Q27304575 | Learning from marketing: Rapid development of medication messages that engage patients |
| Q36654828 | Modeling and Cost-Effectiveness in HIV Prevention |
| Q90371913 | Multiplexed MRM-based protein quantification of putative prognostic biomarkers for chronic kidney disease progression in plasma |
| Q38646836 | Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. |
| Q49954920 | On the rationale of population screening for chronic kidney disease: a public health perspective |
| Q51064420 | Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP". |
| Q35904606 | Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles |
| Q40496392 | PrEP Whores and HIV Prevention: The Queer Communication of HIV Pre-Exposure Prophylaxis (PrEP). |
| Q28080301 | Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How |
| Q36853885 | Preexposure prophylaxis for adolescents and young adults at risk for HIV infection: is an ounce of prevention worth a pound of cure? |
| Q40542860 | Prevalence and recognition of chronic kidney disease in Stockholm healthcare |
| Q90182808 | Preventing CKD in Developed Countries |
| Q38057664 | Proteinuria and progression of glomerular diseases |
| Q36528196 | Recommendations for lab-based screening tests for adult women |
| Q30234324 | Reducing the costs of chronic kidney disease while delivering quality health care: a call to action |
| Q34489517 | Risk models to predict chronic kidney disease and its progression: a systematic review. |
| Q38256787 | Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies |
| Q34455134 | Routine screening for CKD should be done in asymptomatic adults... selectively |
| Q26829238 | Self-management interventions in stages 1 to 4 chronic kidney disease: an integrative review |
| Q49073087 | Should screening of renal markers be recommended in a working population? |
| Q47161734 | Statin Use and Survival After Acute Kidney Injury |
| Q28554193 | Statins and Renin Angiotensin System Inhibitors Dose-Dependently Protect Hypertensive Patients against Dialysis Risk |
| Q36399904 | Statins to improve cardiovascular outcomes in treated HIV infection |
| Q52682754 | Study protocol: rationale and design of the community-based prospective cohort study of kidney function and diabetes in rural New Mexico, the COMPASS study. |
| Q30744184 | Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice |
| Q33855920 | The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States |
| Q28487926 | The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies |
| Q47810963 | The cost of science : knowledge and ethics in the HIV pre-exposure prophylaxis trials |
| Q38656815 | The effect of prevention methods on reducing sexual risk for HIV and their potential impact on a large-scale: a literature review |
| Q58091127 | The epidemiology of chronic kidney disease and the association with non-communicable and communicable disorders in a population of sub-Saharan Africa |
| Q39404544 | The importance of extended high viremics in models of HIV spread in South Africa |
| Q36875566 | The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol |
| Q37065593 | The unjustified classification of kidney donors as patients with CKD: critique and recommendations |
| Q39556962 | Treatment targets in the management of dyslipidemias: which targets in whom? |
| Q92731892 | Trends in kidney function testing in UK primary care since the introduction of the quality and outcomes framework: a retrospective cohort study using CPRD |
| Q36406244 | Trends in serum creatinine testing in Oxfordshire, UK, 1993-2013: a population-based cohort study |
| Q36816377 | Use of antiretrovirals for HIV prevention: what do we know and what don't we know? |
| Q55464528 | Using Normalization Process Theory in feasibility studies and process evaluations of complex healthcare interventions: a systematic review. |
| Q37626053 | Vulnerable infected populations and street markets for ARVs: Potential implications for PrEP rollout in the USA. |
| Q37229172 | Willingness to Take, Use of, and Indications for Pre-exposure Prophylaxis Among Men Who Have Sex With Men-20 US Cities, 2014. |
| Q38717420 | Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia |